References
- Baschant U, Lane NE, Tuckermann J. (2012). The multiple facets of glucocorticoid action in rheumatoid arthritis. Nat Rev Rheumatol 8:645–55.
- Crielaard BJ, Rijcken CJ, Quan L, et al. (2012). Glucocorticoid-loaded core-cross-linked polymeric micelles with tailorable release kinetics for targeted therapy of rheumatoid arthritis. Angew Chem 124:7366–70.
- Feldmann M, Brennan FM, Maini RN. (1996). Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397–440.
- Krasselt M, Baerwald C. (2014). The current relevance and use of prednisone in rheumatoid arthritis. Expert Rev Clin Immunol 10:557–71.
- Lee MK, Lim SJ, Kim CK. (2007). Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 28:2137–42.
- Li HM, Fu Y, Zhang T, et al. (2015). Rational design of polymeric hybrid micelles with highly tunable properties to co-deliver MicroRNA-34a and vismodegib for melanoma therapy. Adv Funct Mater 25:7457–69.
- Li CH, Li HM, Wang Q, et al. (2017). pH-sensitive polymeric micelles for targeted delivery to inflamed joints. J Control Release 246:133–41.
- Liu XM, Quan L, Tian J, et al. (2010). Syntheses of click PEG-Dexamethasone conjugates for the treatment of rheumatoid arthritis. Biomacromolecules 11:2621–8.
- McInnes IB, Schett G. (2007). Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7:429–42.
- Nedvetzki S, Walmsley M, Alpert E, et al. (1999). CD44 involvement in experimental collagen-induced arthritis (CIA). J Autoimmun 13:39–47.
- Naor D, Nedvetzki S. (2003). CD44 in rheumatoid arthritis. Arthritis Res Ther 5:105–15.
- Sattar N, McCarey DW, Capell H, McInnes IB. (2003). Explaining how “High-Grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108:2957–63.
- Shen HX, Shi SJ, Zhang ZR, et al. (2015). Coating solid lipid nanoparticles with hyaluronic acid enhances antitumor activity against melanoma stem-like cells. Theranostics 5:755–71.
- Shin JM, Kim SH, Thambi T, et al. (2014). A hyaluronic acid-methotrexate conjugate for targeted therapy of rheumatoid arthritis. Chem Commun (Camb) 50:7632–5.
- Si J, Shao S, Shen Y, Wang K. (2016). Macrophages as active nanocarriers for targeted early and adjuvant cancer chemotherapy. Small 12:5108–17.
- Smolen JS, Steiner G. (2003). Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2:473–88.
- Sun TM, Du JZ, Yao YD, et al. (2011). Simultaneous delivery of siRNA and paclitaxel via a “Two-in-One” micelleplex promotes synergistic tumor suppression. Acs Nano 5:1483–94.
- Ulmansky R, Turjeman K, Baru M, et al. (2012). Glucocorticoids in nano-liposomes administered intravenously and subcutaneously to adjuvant arthritis rats are superior to the free drugs in suppressing arthritis and inflammatory cytokines. J Control Release 160:299–305.
- Wang D, Goldring SR. (2011). The bone, the joints and the Balm of Gilead. Mol Pharm 8:991–3.
- Wang Q, Sun X. (2017). Recent advances in nanomedicines for the treatment of rheumatoid arthritis. Biomater Sci 5:1407–20.
- Wang Q, Jiang JY, Chen WF, et al. (2016). Targeted delivery of low-dose dexamethasone using PCL-PEG micelles for effective treatment of rheumatoid arthritis. J Control Release 230:64–72.
- Wissing SA, Kayser O, Muller RH. (2004). Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56:1257–72.
- Yuan F, Quan LD, Cui L, et al. (2012). Development of macromolecular prodrug for rheumatoid arthritis. Adv Drug Deliv Rev 64:1205–9.
- Yang M, Feng X, Ding J, et al. (2017). Nanotherapeutics relieve rheumatoid arthritis. J Control Release 252:108–24.